NCT07023588View on ClinicalTrials.gov

Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

May 31, 2029

Study Completion Date

May 31, 2029

Conditions
Acute Myeloid Leukemia (AML)
Interventions
DRUG

Venetoclax

Patients identified with a suboptimal response to chemotherapy based on minimal residual disease (MRD) levels in peripheral blood on Day 6 will initiate venetoclax therapy added on Day 8, administered for 7 days.

Trial Locations (1)

130000

RECRUITING

The First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

Yehui Tan

OTHER

NCT07023588 - Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease | Biotech Hunter | Biotech Hunter